On October 10, 2025, Aptorum Group Ltd entered into a securities purchase agreement to sell 1,000,000 Class A ordinary shares and restricted warrants for about $2 million, with proceeds intended for working capital and costs related to a future merger. The offering closed on October 14, 2025, and is part of their strategy to fund their merger with DiamiR Biosciences Corp.